Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
ConclusionWeekly s.c. injections with 2 mg of exenatide maintains endogenous total GLP-1 levels and lowers circulating DPP-4 levels. This adds an argument in favor of using exenatide in the treatment of pediatric obesity.Clinical trial registrationclinicaltrials.gov, identifier NCT02794402
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
More News: Austria Health | Byetta | Clinical Trials | Eating Disorders & Weight Management | Endocrinology | Hormones | Insulin | Obesity | Pediatrics | Study | Sweden Health